

Immunity after the BNT162b2 Vaccine in Israel. NEJM. <https://www.nejm.org/doi/full/10.1056/NEJMoa2114228> ?

Best regards,

5.1.2e



5.1.2e

www.santepubliquefrance.fr

Retrouvez-nous sur     



De [redacted] 5.1.5 <[redacted]> @ecdc.europa.eu>

Envoyé : mardi 23 novembre 2021 10:00

À : [redacted] <[redacted]> @ordensklubnikum.at>; [redacted] <[redacted]> @vzbb.sk>; [redacted] <[redacted]> @ch.l.lu>; [redacted] <[redacted]> @santepubliquefrance.fr>; [redacted] <[redacted]> @iss.it>; [redacted] <[redacted]> @fhi.no>; [redacted] <[redacted]> @gov.mt>; [redacted] <[redacted]> @landlaeknir.is>; [redacted] <[redacted]> @mphs.moh.gov.cy>; [redacted] <[redacted]> @rki.de>; [redacted] <[redacted]> @ssi.dk>; [redacted] <[redacted]> @phonecoop.coop>; [redacted] <[redacted]> @sam.lt>; [redacted] <[redacted]> @nijz.si>; [redacted] <[redacted]> @hzjz.hr>; [redacted] <[redacted]> @szu.cz>; [redacted] <[redacted]> @hpsc.ie>; [redacted] <[redacted]> @insa.min-saude.pt>; [redacted] <[redacted]> @spkc.gov.lv>; [redacted] <[redacted]> @insp.gov.ro>; [redacted] <[redacted]> @tcd.ie>; [redacted] <[redacted]> @pzh.gov.pl>; [redacted] <[redacted]> @thl.fi>; [redacted] <[redacted]> @msssi.es>; [redacted] <[redacted]> @med.uoa.gr>; [redacted] <[redacted]> @folkhalsomyndigheten.se>; [redacted] <[redacted]> @rivm.nl>; [redacted] <[redacted]> @rivm.nl>; [redacted] <[redacted]> @sciensano.be>; [redacted] <[redacted]> @nnk.gov.hu>

Cc : [redacted] <[redacted]> @ecdc.europa.eu>; [redacted] <[redacted]> @ecdc.europa.eu>; [redacted] <[redacted]> @ecdc.europa.eu>; [redacted] <[redacted]> @who.int>; [redacted] <[redacted]> @yahoo.com>; [redacted] <[redacted]> @nnk.gov.hu>; [redacted] <[redacted]> @ages.at>; [redacted] <[redacted]> @thl.fi>; [redacted] <[redacted]> @ec.europa.eu>; [redacted] <[redacted]> @arsnorte.min-saude.pt>; [redacted] <[redacted]> @mphs.moh.gov.cy>; [redacted] <[redacted]> @telefonica.net>; [redacted] <[redacted]> @hpsc.ie>; [redacted] <[redacted]> @szu.cz>; [redacted] <[redacted]> @eody.gov.gr>; [redacted] <[redacted]> @inmi.it>; [redacted] <[redacted]> @nijz.si>; [redacted] <[redacted]> @jfm.uniba.sk>; [redacted] <[redacted]> @bkus.lv>; [redacted] <[redacted]> @santepubliquefrance.fr>; [redacted] <[redacted]> @ec.europa.eu>; [redacted] <[redacted]> @terviseamet.ee>; [redacted] <[redacted]> @sciensano.be>; [redacted] <[redacted]> @folkhalsomyndigheten.se>; [redacted] <[redacted]> @isciii.es>; [redacted] <[redacted]> @gmail.com>; [redacted] <[redacted]> @gov.mt>; [redacted] <[redacted]> @hi.lt>; [redacted] <[redacted]> @pzh.gov.pl>; [redacted] <[redacted]> @ecdc.europa.eu>; [redacted] <[redacted]> @RIVM.NL>; [redacted] <[redacted]> @ssi.dk>; [redacted] <[redacted]> @rki.de>; [redacted] <[redacted]> @ec.europa.eu>

Objet : FOR YOUR INFORMATION: Upcoming ECDC Rapid Risk Assessment - Assessing the current SARS-CoV-2 epidemiological situation

Importance : Haute

Dear Members of the Advisory Forum,

Please find enclosed, for your information, the rapid risk assessment “Assessing the current SARS-CoV-2 epidemiological situation, projections for the end-of-year festive season and strategies for response in the EU/EEA, 17th update”, due to be published tomorrow, Wednesday the 24th November, 2021.

We recognise the exceptional approach in our procedure of sharing the Rapid Risk Assessment with you so close to publication, and we thank you for your understanding.

With kind regards,
Executive Office-Governance
On behalf of the ECDC PHE Team

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.